- New
Retartrutide (LY-3437943) is a drug intended for the treatment of obesity. It is a triple receptor agonist for GLP-1 (Glucagon-like peptide-1), GIP (Gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). Retartrutide is a 39-amino acid peptide that is resistant to cleavage by DPP4, the enzyme that cleaves GLP-1 and GIP. Retartrutide is constructed from a GIP peptide backbone to achieve triple agonist activity against GLP-1R, GIP, and GCGR.
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
Treatment of type 2 diabetes mellitus and weight loss. Retartrutide is used to improve glycemic control in combination with diet and exercises.
Retartrutide exerts its therapeutic effect through several mechanisms.
Clinical studies have shown that Retatrutide can lead to weight loss in as little as 4 weeks. Results from clinical trials demonstrate that in adults with obesity or overweight (non-diabetic) who are treated with Retatrutide, body weight loss can reach 15-35% after completion of treatment.
Alternative product names: Injectable Hilma Biocare steroid
retatrutide, hilma biocare, triple agonist, GLP-1, GIP, glucagon, weight loss, fat loss, metabolic health, peptides, research chemical, shophilma